Compare Motorola Solutions Inc (MSI) vs TG Therapeutics Inc (TGTX) Price & Performance

Motorola Solutions (MSI) trades at $468.70, up 1.45% on the day, reflecting strong momentum after Q2 2026 earnings beat estimates. The stock shows bullish technical signals with a golden cross pattern and is near its pivot point of $467. Fundamentally, revenue grew 13% year-over-year in Q2, with record backlog of $15.6 billion driving raised full-year guidance. Valuation ratios remain elevated with a P/E of 36.79, while profitability is robust with a net margin of 17.44% and ROE of 91.98%.

Outlook is positive given strong demand in public safety segments and upward earnings revisions, but risks include high valuation sensitivity and execution challenges. The consensus price target of $533.80 implies ~14% upside, supported by 71% analyst buy ratings. Investors should weigh growth prospects against premium multiples and monitor cash flow trends amid significant investing outflows.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.